5NRA.F NANOBIOTIX S.A. SP.ADR

Healthcare Biotechnology Frankfurt Exchange
27.60 EUR
Close of Nov 11, 2026
16.60 47.40
Market cap
EUR 1.41B
P/E
-
P/B
59.16x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 5NRA.F undervalued?

Graham number

The Graham number of NANOBIOTIX S.A. SP.ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NANOBIOTIX S.A. SP.ADR fundamental analysis

No fundamental analysis for NANOBIOTIX S.A. SP.ADR yet.

NANOBIOTIX S.A. SP.ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NANOBIOTIX S.A. SP.ADR

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to de…

Full company profile